ArticleEMBO molecular medicine2022
A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC.
Yue Lu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
17 papers cite it
this paperpooled itcites it